FTRE Quote, Financials, Valuation and Earnings

Cytokinetics, Inc. has a net margin of -2.27% compared to Fortrea Holdings, Inc.'s net margin of -15814.98%. Fortrea Holdings, Inc.'s return on equity of -104.76% beat Cytokinetics, Inc.'s return on equity of --.

Fortrea Holdings, Inc. has a consensus price target of $11.25, signalling downside risk potential of -22.81%. On the other hand Cytokinetics, Inc. has an analysts' consensus of $79.56 which suggests that it could grow by 23.04%. Given that Cytokinetics, Inc. has higher upside potential than Fortrea Holdings, Inc., analysts believe Cytokinetics, Inc. is more attractive than Fortrea Holdings, Inc..

Fortrea Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cytokinetics, Inc. has a beta of 0.584, suggesting its less volatile than the S&P 500 by 41.614%.

Fortrea Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortrea Holdings, Inc. pays -- of its earnings as a dividend. Cytokinetics, Inc. pays out -- of its earnings as a dividend.

Fortrea Holdings, Inc. quarterly revenues are $701.3M, which are larger than Cytokinetics, Inc. quarterly revenues of $1.9M. Fortrea Holdings, Inc.'s net income of -$15.9M is higher than Cytokinetics, Inc.'s net income of -$306.2M. Notably, Fortrea Holdings, Inc.'s price-to-earnings ratio is -- while Cytokinetics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortrea Holdings, Inc. is 0.48x versus 88.23x for Cytokinetics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Humana, Inc. has a net margin of -2.27% compared to Fortrea Holdings, Inc.'s net margin of 0.59%. Fortrea Holdings, Inc.'s return on equity of -104.76% beat Humana, Inc.'s return on equity of 7.3%.

Fortrea Holdings, Inc. has a consensus price target of $11.25, signalling downside risk potential of -22.81%. On the other hand Humana, Inc. has an analysts' consensus of $287.08 which suggests that it could grow by 11.74%. Given that Humana, Inc. has higher upside potential than Fortrea Holdings, Inc., analysts believe Humana, Inc. is more attractive than Fortrea Holdings, Inc..

Fortrea Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Humana, Inc. has a beta of 0.462, suggesting its less volatile than the S&P 500 by 53.84%.

Fortrea Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Humana, Inc. offers a yield of 1.38% to investors and pays a quarterly dividend of $0.89 per share. Fortrea Holdings, Inc. pays -- of its earnings as a dividend. Humana, Inc. pays out 35.45% of its earnings as a dividend. Humana, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Fortrea Holdings, Inc. quarterly revenues are $701.3M, which are smaller than Humana, Inc. quarterly revenues of $32.6B. Fortrea Holdings, Inc.'s net income of -$15.9M is lower than Humana, Inc.'s net income of $194M. Notably, Fortrea Holdings, Inc.'s price-to-earnings ratio is -- while Humana, Inc.'s PE ratio is 24.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortrea Holdings, Inc. is 0.48x versus 0.25x for Humana, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Opus Genetics, Inc. has a net margin of -2.27% compared to Fortrea Holdings, Inc.'s net margin of -566.87%. Fortrea Holdings, Inc.'s return on equity of -104.76% beat Opus Genetics, Inc.'s return on equity of -490.41%.

Fortrea Holdings, Inc. has a consensus price target of $11.25, signalling downside risk potential of -22.81%. On the other hand Opus Genetics, Inc. has an analysts' consensus of $7.67 which suggests that it could grow by 266.83%. Given that Opus Genetics, Inc. has higher upside potential than Fortrea Holdings, Inc., analysts believe Opus Genetics, Inc. is more attractive than Fortrea Holdings, Inc..

Fortrea Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Opus Genetics, Inc. has a beta of 0.418, suggesting its less volatile than the S&P 500 by 58.186%.

Fortrea Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Opus Genetics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortrea Holdings, Inc. pays -- of its earnings as a dividend. Opus Genetics, Inc. pays out -- of its earnings as a dividend.

Fortrea Holdings, Inc. quarterly revenues are $701.3M, which are larger than Opus Genetics, Inc. quarterly revenues of $3.1M. Fortrea Holdings, Inc.'s net income of -$15.9M is higher than Opus Genetics, Inc.'s net income of -$17.5M. Notably, Fortrea Holdings, Inc.'s price-to-earnings ratio is -- while Opus Genetics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortrea Holdings, Inc. is 0.48x versus 7.12x for Opus Genetics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -2.27% compared to Fortrea Holdings, Inc.'s net margin of 33.68%. Fortrea Holdings, Inc.'s return on equity of -104.76% beat Merck & Co., Inc.'s return on equity of 39.63%.

Fortrea Holdings, Inc. has a consensus price target of $11.25, signalling downside risk potential of -22.81%. On the other hand Merck & Co., Inc. has an analysts' consensus of $105.35 which suggests that it could grow by 3.01%. Given that Merck & Co., Inc. has higher upside potential than Fortrea Holdings, Inc., analysts believe Merck & Co., Inc. is more attractive than Fortrea Holdings, Inc..

Fortrea Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

Fortrea Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.17% to investors and pays a quarterly dividend of $0.81 per share. Fortrea Holdings, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Fortrea Holdings, Inc. quarterly revenues are $701.3M, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Fortrea Holdings, Inc.'s net income of -$15.9M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Fortrea Holdings, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 13.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortrea Holdings, Inc. is 0.48x versus 4.03x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.